Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 28

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 28
---
 trials and activities related to regulatory filings for our product candidates, including regulatory consultants.

			●

			General and administrative (G&A) expenses were $1.0 million for each of the three months ended June 30, 2025 and June 30, 2024, as a decrease in salaries and related costs was offset by an increase in noncash share-based compensation and professional service fees. Our G&A expenses consist primarily of salaries and related costs for our employees in administrative, executive and finance functions. G&A expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, office, and travel expenses.

Total other income decreased by $110,000 to $154,000 for the three months ended June 30, 2025 compared to $264,000 for the same period last year and was composed of the following:

			●

			Grant income decreased by $53,000 to $183,000 for the three months ended June 30, 2025 compared to $236,000 for the three months ended June 30, 2024. The decrease is related to the grant income associated with the activities under the 2023 SIF Agreement.

			●

			Interest income decreased to $600 for the three months ended June 30, 2025 compared to $33,000 for the same period last year primarily due to lower cash balances.

			●

			Foreign exchange loss was $30,000 for the three months ended June 30, 2025 compared to a loss of $5,000 for the same period last year.

For the three months ended June 30, 2025, our net loss was $1.7 million, or $0.25 per common share, compared to a net loss of $1.7 million, or $0.52 per common share for the three months ended June 30, 2024.

21

Comparison of the Nine Months Ended June 30, 2025 and 2024

Total operating expenses decreased by $0.6 million to $5.4 million for the nine months ended June 30, 2025 compared to $6.0 million for the nine months ended June 30, 2024.

			●

			The following table summarizes our R&D expenses incurred during the nine months ended June 30, 2025 and 2024, together with the dollar increase or decrease in those items:

			Nine Months